These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 28923209)
1. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209 [TBL] [Abstract][Full Text] [Related]
2. The value and effectiveness of angiogenesis inhibitors for colorectal cancer. Venook AP Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184 [No Abstract] [Full Text] [Related]
3. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? Giampieri R; Caporale M; Pietrantonio F; De Braud F; Negri FV; Giuliani F; Pusceddu V; Demurtas L; Restivo A; Fontanella C; Aprile G; Cascinu S; Scartozzi M Crit Rev Oncol Hematol; 2016 Apr; 100():99-106. PubMed ID: 26907512 [TBL] [Abstract][Full Text] [Related]
4. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer? Saif MW Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885 [TBL] [Abstract][Full Text] [Related]
7. Emerging VEGF-receptor inhibitors for colorectal cancer. Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053 [TBL] [Abstract][Full Text] [Related]
8. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Tapia Rico G; Townsend AR; Broadbridge V; Price TJ Drugs Aging; 2017 Mar; 34(3):173-189. PubMed ID: 28197947 [TBL] [Abstract][Full Text] [Related]
9. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy with molecular targeting agents for colorectal cancer]. Bando H; Ohtsu A Nihon Rinsho; 2012 Nov; 70 Suppl 8():468-74. PubMed ID: 23513885 [No Abstract] [Full Text] [Related]
11. Angiogenesis in Colorectal Cancer: Antibodies. Chan E Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595 [TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic Therapy in Colorectal Cancer. Mody K; Baldeo C; Bekaii-Saab T Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079 [TBL] [Abstract][Full Text] [Related]
13. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective. Clarke JM; Hurwitz HI; Rangwala F Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778 [TBL] [Abstract][Full Text] [Related]
14. Targeting Angiogenesis in Colorectal Carcinoma. Lopez A; Harada K; Vasilakopoulou M; Shanbhag N; Ajani JA Drugs; 2019 Jan; 79(1):63-74. PubMed ID: 30617958 [TBL] [Abstract][Full Text] [Related]
15. Targeting Angiogenesis in Colorectal Cancer: Tyrosine Kinase Inhibitors. Kircher SM; Nimeiri HS; Benson AB Cancer J; 2016; 22(3):182-9. PubMed ID: 27341596 [TBL] [Abstract][Full Text] [Related]
16. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. Chung C; Pherwani N Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964 [TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. Papadimitriou M; Papadimitriou CA Anticancer Res; 2021 Feb; 41(2):567-582. PubMed ID: 33517262 [TBL] [Abstract][Full Text] [Related]
18. How to Manage the Side Effects of New Targets Agents for Metastatic Colorectal Cancer. Becze E ONS Connect; 2016 Jan; 31(1):24-5. PubMed ID: 26887105 [No Abstract] [Full Text] [Related]